Protein Kinase Inhibitors: all 15,766 studies that test it

Page 23 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)RecruitingNCT05233332Phase 2
• Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBCRecruitingNCT05228951Phase 2
• Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTTRecruitingNCT05225116Phase 1
• SOLIDARITY Finland Plus Long-COVIDRecruitingNCT05220280Phase 4
• Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic CancerRecruitingNCT05218889Phase 1/2
• Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLCNot yet recruitingNCT05218759Not applicable
• Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic CancerRecruitingNCT05218629Phase 2
• A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune ThrombocytopeniaRecruitingNCT05214391Phase 2
• Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05214222Phase 2
• Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System LymphomaRecruitingNCT05209620Phase 2
• (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsRecruitingNCT05208047Phase 3
• Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid TumorsRecruitingNCT05207787Phase 1/2
• Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02RecruitingNCT05205200Phase 2
• A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus CrizotinibNot yet recruitingNCT05204628Phase 3
• The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingNCT05203172Phase 4
• Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary ThrombocytopeniaRecruitingNCT05199909Phase 2
• A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLRecruitingNCT05197192Phase 3
• Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCCNot yet recruitingNCT05195294Phase 2
• Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell CarcinomaNot yet recruitingNCT05189184Phase 2
• First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural MesotheliomaRecruitingNCT05188859Phase 2
• An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast CancerRecruitingNCT05186545Phase 2
• A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung CancerNot yet recruitingNCT05186506Phase 2
• SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic CancerNot yet recruitingNCT05185869Phase 2
• Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)RecruitingNCT05185739Phase 2
• A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)RecruitingNCT05182931Phase 2
• A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative ColitisRecruitingNCT05181137Phase 3
• Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 InhibitorRecruitingNCT05181033Phase 2
• Pediatric Low Grade Glioma - MEKinhibitor TRIal vs ChemotherapyRecruitingNCT05180825Phase 2
• Zanubrutinib and Venetoclax in CLL (ZANU-VEN)RecruitingNCT05168930Phase 2
• Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT05168566Phase 2
• Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01）RecruitingNCT05167994Phase 2
• Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)RecruitingNCT05165407Phase 2
• Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.Not yet recruitingNCT05162898Not applicable
• The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
• Extension Study of Infigratinib in Children With Achondroplasia (ACH)Enrolling by invitationNCT05145010Phase 2
• A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid TumorsRecruitingNCT05135975Phase 2
• A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AMLRecruitingNCT05133882Phase 1/2
• Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung AdenocarcinomaNot yet recruitingNCT05132985Phase 2
• A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingNCT05128825Phase 2
• A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)RecruitingNCT05118789Phase 1/2
• Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System LymphomaRecruitingNCT05117814Not applicable
• Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerRecruitingNCT05113537Phase 1/2
• Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian CancerRecruitingNCT05113368Phase 2
• Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial CancerRecruitingNCT05112991Phase 2
• Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative ColitisNot yet recruitingNCT05112263Not applicable
• Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast CancerRecruitingNCT05111561Phase 1
• Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus PemNot yet recruitingNCT05106127Phase 2
• Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention StudyRecruitingNCT05104983Phase 2
• A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerRecruitingNCT05104788Phase 2
• First in Human Study of UCT-03-008 in Participants With Advanced Solid TumorsRecruitingNCT05103046Phase 1
• Comparison of Tofacitinib and Methotrexate in Takayasu's ArteritisRecruitingNCT05102448Phase 4
• Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid TumorsRecruitingNCT05098847Phase 2
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerRecruitingNCT05098210Phase 1
• Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast CancerRecruitingNCT05095207Phase 1/2
• A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal CancerRecruitingNCT05093907Phase 1/2
• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxRecruitingNCT05092373Phase 1
• To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaRecruitingNCT05090891Phase 2
• Norursodeoxycholic Acid vs. Placebo in NASHRecruitingNCT05083390Phase 2
• The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast CancerRecruitingNCT05075512Phase 2
• IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.RecruitingNCT05073250Phase 2
• Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" StudyNot yet recruitingNCT05067530Phase 2
• Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesRecruitingNCT05064280Phase 2
• Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular CarcinomaRecruitingNCT05057845Phase 2
• Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver MetastasisRecruitingNCT05057052Phase 2
• Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine TumorsRecruitingNCT05048901Phase 1/2
• A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingNCT05048212Phase 2
• Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular CarcinomaRecruitingNCT05048017Phase 2
• A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerRecruitingNCT05042375Phase 3
• Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic CholangiocarcinomaNot yet recruitingNCT05039892Phase 2
• A Study of Elritercept Alone or Together With Ruxolitinib in Adults With MyelofibrosisRecruitingNCT05037760Phase 2
• COAST Therapy in Advanced Solid Tumors and Prostate CancerRecruitingNCT05036226Phase 1/2
• TAS-102 and Anlotinib in ≥3 Lines mGCRecruitingNCT05029102Phase 2
• A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological CancerRecruitingNCT05028504Phase 2
• Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System MetastasesRecruitingNCT05026983Phase 2
• Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AMLRecruitingNCT05024552Phase 1
• Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Phase 1/2
• Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS StudyRecruitingNCT05019703Phase 2
• Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast CancerRecruitingNCT05019690Phase 1/2
• A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine CarcinomaRecruitingNCT05015621Phase 3
• ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell CarcinomaRecruitingNCT05014464Phase 2
• Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLCRecruitingNCT05011487Phase 2
• Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionRecruitingNCT05010772Phase 1
• Lenvatinib Plus Sintilimab in Patients with Immune Checkpoint Inhibitor Previously Treated Advanced Liver CancerRecruitingNCT05010681Phase 2
• ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT05010122Phase 1/2
• A Study of Ruxolitinib and Duvelisib in People With LymphomaRecruitingNCT05010005Phase 1
• Combination Therapy for the Treatment of Diffuse Midline GliomasRecruitingNCT05009992Phase 2
• Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)RecruitingNCT05009927Phase 2
• Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung CancerRecruitingNCT05004974Phase 2
• A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor CancerRecruitingNCT05004116Phase 1/2
• ConsideRAte Study - Splenic Stimulation for RARecruitingNCT05003310Not applicable
• Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesRecruitingNCT05000294Phase 1/2
• (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisRecruitingNCT04996875Phase 2
• A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid TumorsRecruitingNCT04996121Phase 1/2
• A Study of LP-168 in Participants With Relapse or Refractory B-Cell LymphomaRecruitingNCT04993690Phase 1
• Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)RecruitingNCT04989621Phase 2
• Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in InfantsRecruitingNCT04987463Phase 2/3
• Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)RecruitingNCT04985435Phase 4
• A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruitingNCT04985266Phase 2
• A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and LymphomaRecruitingNCT04983810Phase 1/2
• Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerRecruitingNCT04981509Phase 2

← Protein Kinase Inhibitors overview